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Background: Although previous studies have shown a positive association between bisphosphonates and atrial fibrillation or atrial flutter (AF) 
in women, this relationship has not been demonstrated in men. We hypothesize that bisphosphonate use is associated with AF in a population of 
community-dwelling men.
Methods: MrOS is a prospective cohort study of 5,995 U.S. men ages 65 and older from six clinical sites enrolled in 2000-2002. This analysis 
used cross-sectional data from a subset of 2,911 men who participated in the sleep visit (2003-2005), had continuous overnight sleep studies 
with electrocardiogram data that were centrally reviewed for the presence or absence of AF (of any duration), and had medication use data. Logistic 
regression models were used to estimate the likelihood of AF among bisphosphonate users (compared to nonusers). 
Results: Of the 2,911 men included in this analysis, 123 were bisphosphonate users and 2,788 were nonusers. The two groups did not differ 
in age or most cardiovascular risk factors (self-reported). The mean age was 76.4 years, 49.9% had hypertension, 14.0% had previous coronary 
revascularization, 6.0% had congestive heart failure, 11.0% had a previous stroke or transient ischemic attack, and 13.3% were diabetics. AF was 
present in 138 participants (4.8%). In the unadjusted model, bisphosphate users had increased odds of AF, but this association did not achieve 
statistical significance (odds ratio 1.84, 95% CI 0.94-3.60). However, in the multivariable model that was adjusted for confounders including age, 
clinic site, body mass index, femoral neck bone mineral density, and self-reported cardiovascular risk factors, there was a significant association 
between current bisphosphonate use and AF (odds ratio 2.25, 95% CI 1.12-4.55). In an additional sensitivity analysis, excluding 17 previous users of 
bisphosphonates, this association remained (odds ratio 2.27, 95% CI 1.12-4.58).
Conclusions: These results support an association of bisphosphonate use and AF in a population of community-dwelling men over age 65. As there 
are potentially profound clinical implications of bisphosphonate use and AF, further research is needed to investigate this relationship.
